comparemela.com

Latest Breaking News On - Daniel gaudet - Page 1 : comparemela.com

Arrowhead Pharmaceuticals Presents New Phase 2 Data of Plozasiran in Patients with Mixed Hyperlipidemia

- Plozasiran significantly lowered triglyceride levels with commensurate reductions in APOC3, non-HDL-C, and remnant cholesterol - Data presented at European Atherosclerosis Society 92nd Congress.

Daniel gaudetColl cardiolGugliucciaj clinRobert rosensonChristiem ballantyneBaylor college of medicineArrowhead pharmaceuticals incExchange commissionEuropean atherosclerosis societyArrowhead pharmaceuticalsEuropean medicines agencyDrug administrationNew england journalBaylor collegePrincipal investigatorAtherosclerosis society

Promising Hyperlipidemia Treatment Lowers Cardiovascular Risk

Promising Hyperlipidemia Treatment Lowers Cardiovascular Risk
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

United statesBaylor college of medicineRoberts rosensonJennifer hellawellDaniel gaudetRong zhouMaan mushinPeter cliftonNicholasj leeperChristie ballantyneStacey melquistMasoud azizadArrowhead pharmaceuticalsStanford universityTexas heart instituteBaylor college

Daniel Gaudet, MD, PhD: Contextualizing Plozasiran Data from SHASTA-2, Upcoming MUIR Data

Daniel Gaudet, MD, PhD, discusses SHASTA-2 data and what cardiologists could learn from the forthcoming 48-week MUIR trial data from EAS 2024.

Daniel gaudetEli lillyBoehringer ingelheimAmerican college of cardiologyNovo nordiskArrowhead pharmaceuticalsAmerican collegeAnnual scientific sessionArrowhead pharmaceuticalNew amsterdam pharma

Triglyceride-Lowering Therapies Provide Favorable Outcomes in Early Testing

In Bridge-TIMI 73a and SHASTA-2, the RNA-silencing therapies cut triglycerides quickly, offering hope for hard-to-treat patients.

University of pennsylvaniaUnited statesWestern australiaDaniel sofferBrian bergmarkDaniel gaudetGerald wattsNeha pagidipatiPradeep natarajanPhd university of western australiaPhd university of montrealMd duke university school of medicineIonis pharmaceuticalsMd university of pennsylvania school medicineArrowhead pharmaceuticalsDrug administration

Substantial Triglyceride Reduction With Plozasiran

In patients with severe hypertriglyceridemia who are at risk for acute pancreatitis, the drug brought about triglyceride reductions of more than 50% in the phase 2 SHASTA-2 study.

United statesNorth carolinaNeha pagidipatiDaniel gaudetUniversity of montrealAmerican college of cardiology annual scientific sessionDuke clinical research instituteAmerican collegeAnnual scientific sessionIpid managementCv riskCardiovascular riskV risk factorsCardiovascular risk factorsCardiovascular risk managementAbdominal infection

vimarsana © 2020. All Rights Reserved.